https://mavenbio.com/ 2026-01-09T00:00:00.000Z weekly 1 https://mavenbio.com/products/smart-tables 2026-01-09T00:00:00.000Z weekly 0.8 https://mavenbio.com/products/report-builder 2026-01-09T00:00:00.000Z weekly 0.8 https://mavenbio.com/products/research-agent 2026-01-09T00:00:00.000Z weekly 0.8 https://mavenbio.com/products/watchlists 2026-01-09T00:00:00.000Z weekly 0.8 https://mavenbio.com/solutions/consultants 2026-01-09T00:00:00.000Z monthly 0.8 https://mavenbio.com/solutions/investment-firms 2026-01-09T00:00:00.000Z monthly 0.8 https://mavenbio.com/solutions/pharma-biotech 2026-01-09T00:00:00.000Z monthly 0.8 https://mavenbio.com/research 2026-01-09T00:00:00.000Z weekly 0.8 https://mavenbio.com/contact 2026-01-09T00:00:00.000Z monthly 0.7 https://mavenbio.com/privacy 2026-01-09T00:00:00.000Z yearly 0.3 https://mavenbio.com/terms 2026-01-09T00:00:00.000Z yearly 0.3 https://mavenbio.com/research/top-10-biopharma-market-cap-gains-september-2023-vs-2024 2024-09-27T21:32:47Z monthly 0.7 https://mavenbio.com/research/top-10-pharma-companies-by-revenue 2024-06-28T12:46:20Z monthly 0.7 https://mavenbio.com/research/ira-s-first-10-how-much-revenue-is-at-stake 2024-08-21T16:34:35Z monthly 0.7 https://mavenbio.com/research/radiopharmaceutical-deals-recap 2024-07-15T18:55:21Z monthly 0.7 https://mavenbio.com/research/the-best-selling-neurology-drugs-in-q3_2025-where-multibillion-dollar-franchises-are-taking 2025-12-24T20:29:52Z monthly 0.7 https://mavenbio.com/research/big-pharma-m-and-a-in-2025-a-shift-toward-derisked-growth 2026-01-08T15:17:08Z monthly 0.7 https://mavenbio.com/research/bms-top-10-medicines-by-sales-in-q2-24 2024-08-14T15:43:52Z monthly 0.7 https://mavenbio.com/research/advancing-beyond-statins-the-landscape-of-emerging-cholesterol-lowering-medicines 2025-12-07T12:33:06Z monthly 0.7 https://mavenbio.com/research/glp-1-small-molecule 2024-07-18T20:25:09Z monthly 0.7 https://mavenbio.com/research/gilead-q2-2025-earnings-hiv-trodelvy 2025-12-22T23:55:24Z monthly 0.7 https://mavenbio.com/research/crowning-achievements-recent-royalty-deals-in-biopharma 2024-09-03T18:20:30Z monthly 0.7 https://mavenbio.com/research/inside-big-pharma-s-portfolios-what-drove-q3-2025-revenue 2025-12-16T19:00:46Z monthly 0.7 https://mavenbio.com/research/abbvie-q2-earnings-immunology-strength-overshadows-aesthetics-challenges 2024-07-31T13:31:25Z monthly 0.7 https://mavenbio.com/research/bladder-cancer-emerging-therapies-and-key-areas-to-watch 2025-04-06T00:27:07Z monthly 0.7 https://mavenbio.com/research/biopharma-s-direct-to-consumer-evolution 2024-09-03T17:03:15Z monthly 0.7 https://mavenbio.com/research/bristol-myers-squibb-at-morgan-stanley-healthcare-conference 2024-09-20T13:12:52Z monthly 0.7 https://mavenbio.com/research/top-10-biopharma-deals-q1-2024 2024-06-28T12:45:22Z monthly 0.7 https://mavenbio.com/research/shifts-in-pharma-revenue-mix-across-leading-portfolios-2019-2024 2026-02-02T15:23:14Z monthly 0.7 https://mavenbio.com/research/beyond-insulin-emerging-disease-modifying-therapies-in-type-1-diabetes-Mellitus 2025-12-29T19:33:23Z monthly 0.7 https://mavenbio.com/research/top-10-biopharma-companies-by-revenue-q2-2024 2024-08-29T17:10:42Z monthly 0.7 https://mavenbio.com/research/astrazeneca-q2-24-earnings-recap 2024-08-14T15:44:59Z monthly 0.7 https://mavenbio.com/research/top-10-medicines-by-q2-2024-sales 2024-08-21T16:32:18Z monthly 0.7 https://mavenbio.com/research/top-15-drugs-by-sales-in-2023 2024-06-28T12:22:34Z monthly 0.7 https://mavenbio.com/research/novartis-navigates-patent-cliff-with-robust-pipeline-and-strategic-focus 2024-06-25T19:49:39Z monthly 0.7 https://mavenbio.com/research/top-10-biopharma-companies-by-q2-2024-sales 2024-09-12T13:12:43Z monthly 0.7 https://mavenbio.com/research/notable-biopharma-fundraises-in-august 2024-09-10T14:06:59Z monthly 0.7 https://mavenbio.com/research/emerging-cholesterol-lowering-therapies 2025-12-22T23:54:44Z monthly 0.7 https://mavenbio.com/research/clinical-stage-kras-therapeutics-how-g12d-and-pan-kras-strategies-are-reshaping-drug-development 2026-01-26T15:03:29Z monthly 0.7 https://mavenbio.com/research/big-pharma-partnerships-in-2023-a-comprehensive-overview 2024-06-28T12:57:22Z monthly 0.7 https://mavenbio.com/research/biopharma-launch-activity-new-molecular-and-biologic-entities-2021-2025 2026-01-19T13:56:24Z monthly 0.7 https://mavenbio.com/research/biotech-ipo-trifecta 2024-09-26T14:49:06Z monthly 0.7 https://mavenbio.com/research/her2-targeted-therapies-solid-tumors 2025-12-22T23:55:34Z monthly 0.7 https://mavenbio.com/research/fda-drug-approvals-in-2025-what-the-year-s-46-new-therapies-reveal-about-industry-direction 2026-01-13T16:18:39Z monthly 0.7 https://mavenbio.com/research/biotech-funding-valuation-shifts-from-seed-to-ipo 2024-09-27T13:43:39Z monthly 0.7 https://mavenbio.com/research/which-large-pharma-companies-spend-the-most-on-Mergers 2024-06-28T12:38:33Z monthly 0.7 https://mavenbio.com/research/the-shifting-spending-priorities-of-big-pharma 2024-07-26T15:34:43Z monthly 0.7 https://mavenbio.com/research/top-10-biopharma-companies-by-revenue-2003-to-2023 2024-08-01T14:30:35Z monthly 0.7 https://mavenbio.com/research/top-15-immunology-drugs-by-sales-of-q1-24 2024-07-01T18:46:33Z monthly 0.7 https://mavenbio.com/research/the-radiopharmaceutical-revolution 2024-10-18T21:25:46Z monthly 0.7 https://mavenbio.com/research/the-constant-evolution-of-biopharma-a-decade-of-transformation 2024-07-08T14:12:14Z monthly 0.7 https://mavenbio.com/research/top-10-immunology-drugs-2023 2024-06-28T12:45:02Z monthly 0.7 https://mavenbio.com/research/pharma-stock-performance-2025-valuation-divide 2025-12-22T23:54:08Z monthly 0.7 https://mavenbio.com/research/merck-post-keytruda-potential-growth-drivers 2024-09-25T13:48:08Z monthly 0.7 https://mavenbio.com/research/upcoming-patent-expirations-for-top-15-drugs 2024-06-28T12:45:44Z monthly 0.7 https://mavenbio.com/research/ai-platforms-for-biotech-and-pharmaceutical-consulting 2025-07-28T16:45:29Z monthly 0.7 https://mavenbio.com/research/merck-s-usd10b-verona-acquisition-ohtuvayre-leads-next-gen-copd-innovation 2025-07-28T16:42:16Z monthly 0.7 https://mavenbio.com/research/sanofi-q2-24-earnings-recap 2024-08-14T15:44:53Z monthly 0.7 https://mavenbio.com/research/j-and-j-s-q2-earnings-and-key-milestones-in-immunology-and-oncology 2024-07-22T14:34:12Z monthly 0.7 https://mavenbio.com/research/top-15-immunology-medicines-by-q2-2024-sales 2024-08-29T17:16:02Z monthly 0.7 https://mavenbio.com/research/roche-10-year-sales-evolution 2024-08-21T16:33:46Z monthly 0.7 https://mavenbio.com/research/lilly-and-novo-how-do-glp-1-sales-compare 2024-08-21T17:08:55Z monthly 0.7 https://mavenbio.com/research/unlocking-innovation-top-ai-use-cases-in-pharma-today 2025-07-28T16:46:01Z monthly 0.7 https://mavenbio.com/research/pfizer-delivers-robust-q2-2024-performance-raises-full-year-guidance 2024-09-13T17:15:08Z monthly 0.7 https://mavenbio.com/research/abbvie-q3-2025-earnings-skyrizi-rinvoq 2025-12-22T23:54:24Z monthly 0.7 https://mavenbio.com/research/dato-dxd 2024-10-18T21:28:25Z monthly 0.7 https://mavenbio.com/research/top-15-oncology-drugs-2023 2024-06-28T12:56:38Z monthly 0.7 https://mavenbio.com/research/market-capitalization-trends-of-leading-pharmaceutical-companies-in-2025 2025-12-22T15:21:58Z monthly 0.7 https://mavenbio.com/research/alzheimer-s-disease-landscape 2024-08-15T14:28:30Z monthly 0.7 https://mavenbio.com/research/how-much-do-large-biopharma-companies-spend-on-capex 2024-08-29T17:22:40Z monthly 0.7 https://mavenbio.com/research/top-15-oncology-medicines-by-q2-2024-sales 2024-08-29T17:04:26Z monthly 0.7 https://mavenbio.com/research/the-prize-of-the-eyes-eylea-and-vabysmo 2024-07-23T19:08:41Z monthly 0.7 https://mavenbio.com/research/top-15-biopharma-companies-by-oncology-sales 2024-06-28T12:57:33Z monthly 0.7 https://mavenbio.com/research/revolutionizing-cancer-treatment-the-emergence-of-mrna-vaccines 2024-09-04T19:21:04Z monthly 0.7 https://mavenbio.com/research/ai-tools-for-pharma-market-research 2025-07-28T16:42:33Z monthly 0.7 https://mavenbio.com/research/pfizer-q3-2025-earnings-portfolio-rebalancing 2025-12-22T23:56:23Z monthly 0.7 https://mavenbio.com/research/who-will-transform-the-hae-market-Ionis-kalvista 2025-04-06T00:48:01Z monthly 0.7 https://mavenbio.com/research/top-ai-platforms-for-life-sciences-investment-banking 2025-08-07T23:05:39Z monthly 0.7 https://mavenbio.com/research/atopic-dermatitis-landscape 2024-08-29T18:06:08Z monthly 0.7 https://mavenbio.com/research/how-drug-pricing-in-the-us-compares-to-other-countries 2024-06-28T12:57:05Z monthly 0.7 https://mavenbio.com/research/johnson-and-johnson-q3-2025-earnings-oncology-and-immunology-drive-growth-after-strategic 2025-12-19T18:04:46Z monthly 0.7 https://mavenbio.com/research/u-s-pharma-manufacturing-and-r-and-d-site-investments-announced-in-2025 2026-01-07T21:50:59Z monthly 0.7 https://mavenbio.com/research/j-and-j-s-q2-highlights-innovative-medicine-drives-growth-despite-stelara-slowdown 2025-08-01T13:53:27Z monthly 0.7 https://mavenbio.com/research/ai-platforms-for-biotech-and-pharmaceutical-equity-research 2025-08-02T14:45:24Z monthly 0.7 https://mavenbio.com/research/top-10-biopharma-fundraises-in-april-2024 2024-06-28T12:38:13Z monthly 0.7 https://mavenbio.com/research/ai-drug-discovery-partnerships 2024-06-28T12:46:37Z monthly 0.7 https://mavenbio.com/research/epidemiologies-of-oncology-insights-from-astrazeneca-and-novartis 2024-09-11T13:19:13Z monthly 0.7 https://mavenbio.com/research/capital-efficiency-in-chinese-biotech-a-comparative-analysis-of-licensing-deal-structures 2026-01-14T21:33:00Z monthly 0.7 https://mavenbio.com/research/a-new-era-in-duchenne-muscular-dystrophy-diseasemodifying-therapies-in-development 2025-12-26T14:54:44Z monthly 0.7 https://mavenbio.com/research/massachusetts-biopharma-vc-funding-h1-2024-vs-h1-2023 2024-09-06T20:17:41Z monthly 0.7 https://mavenbio.com/research/moderna-research-and-development-cut 2024-09-23T13:28:13Z monthly 0.7 https://mavenbio.com/research/select-eli-lilly-u-s-patent-expiries 2024-09-24T16:13:38Z monthly 0.7 https://mavenbio.com/research/us-biotech-ipos-h1-2025-performance 2025-12-22T23:56:49Z monthly 0.7 https://mavenbio.com/research/top-pharmaceutical-r-and-d-spending-in-2025-how-big-pharma-is-allocating-capital-through-nine 2025-12-26T16:27:16Z monthly 0.7 https://mavenbio.com/research/top-20-companies-market-cap-2003-2024 2024-08-01T13:57:34Z monthly 0.7 https://mavenbio.com/research/merck-q3-2025-earnings-keytruda-pipeline 2025-12-22T23:56:09Z monthly 0.7 https://mavenbio.com/research/the-next-generation-of-chronic-spontaneous-urticaria(csu)-treatments-targets-approvals-and-pipeline 2025-12-23T14:18:51Z monthly 0.7 https://mavenbio.com/research/best-selling-immunology-drugs-in-q3-2025-revenue-leaders-and-market-dynamics 2026-01-07T22:04:31Z monthly 0.7 https://mavenbio.com/research/inside-big-pharma-portfolios-part2-what-drove-revenue-in-q3-2025 2025-12-22T15:23:34Z monthly 0.7 https://mavenbio.com/research/new-ema-medicine-approvals-through-august-2024 2024-09-06T20:31:03Z monthly 0.7 https://mavenbio.com/research/esmo-2024-recap-of-notable-advances-in-oncology 2024-09-24T13:12:25Z monthly 0.7 https://mavenbio.com/research/roche-pharmaceutical-division-performance-in-q2-yoy 2024-09-12T20:24:48Z monthly 0.7 https://mavenbio.com/research/15-biggest-biotech-fundraisings-in-q1-2024 2024-06-28T12:56:26Z monthly 0.7 https://mavenbio.com/research/race-for-glp-1-obesity-drugs-heats-up 2024-06-28T12:44:23Z monthly 0.7